微信小陈
微信小章
产品简介
购买须知
| 产品名称： | B7-24-E1G4 CMCC 11060 |
|---|---|
| 商品货号： | TS212636 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain： | Strain: BALB/c (B cell); BALB/c (myeloma) |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with Sp2/0 myeloma cells. |
| Comments： | Animals were immunized with SF9 insect cells expressing recombinant human B7. Spleen cells were fused with Sp2/0 myeloma cells. |
| Complete Growth Medium： | Iscoves modified Dulbeccos medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate supplemented with 1% OPI (0.15 mg/ml oxaloacetate, 0.05 mg/ml pyruvate, 0.0082 mg/ml bovine insulin), 90%; heat-inactivated fetal bovine serum, 10%
|
| Subculturing： | Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) Cultures can be maintained by addition of fresh medium or
replacement of medium. Alternatively, cultures can be
established by centrifugation with subsequent resuspension in fresh medium at 2- 3 x 10 exp5 viable cells/ml. Maintain cell density between 2 X 10 exp5 and 1 X 10 exp6 viable cells/ml. |
| Cryopreservation： | growth medium, 90%; DMSO, 10% |
| Culture Conditions： | Temperature: 37.0°C |
| Name of Depositor： | Chiron Corp. |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | de Boer M, Conroy LB. Anti-CD40 monoclonal antibodies capable of blocking B-cell activation. US Patent 5,677,165 dated Oct 14 1997 |